Chinese Clinical Oncology

Expression and effect of miR-769-5p on proliferation， migration and invasion in non-small cell lung cancer

GAO Peng， YANG Zhao， ZHANG Jie， ZHANG Chao， WANG Wei， ZHAI Hongfang， CHEN Mingda， ZUO Fang， WANG Yan， DU Jiayi， ZHANG Lixin， LI Hongmin， SUN Guogui.

Chinese Clinical Oncology. 2017, 22 (9): 769.

Abstract ( 268 )

PDF（pc） (1796KB) ( 306 )

Save

Objective To explore the expression of miRNA-769-5p （miR-769-5p） in non-small cell lung cancer（NSCLC）and its effect on proliferation， migration and invasion of NSCLC cells.Methods The miR-769-5p expression in NSCLC cell lines （A549， NCI-H1299， NCI-H157， ANIP-973 and GLC-82） was detected by QRT-PCR， and the cell lines of highest and lowest expression of miR-769-5p were applied for the further study. NSCLC cell lines were divided into transfection group and control group， and respectively transfected with miR-769-5p mimics／inhibitor and miRNA mimics control／inhibitor control. Furthermore， cell proliferation， colony formation migration and invasion were respectively analyzed by MST， colony formation， and transwell chamber experiments. Results The expression of miR-769-5p in A549， NCI-H1299， NCI-H157， ANIP-973 and GLC-82 were 0.06， 0.40， 0.09， 1.04 and 2.31. miR-769-5p mimics and miR-769-5p inhibitor were respectively transfected into A549 and GLC-82 cell lines. MST test showed that transfection with miR-769-5p mimics in A549 cells for 48， 72， 96 h significantly inhibited the cell viability （P＜0.05）. The colony formation （124.7±14.7 vs. 399.4±46.0，P＜0.05）， migration （94.4±18.1 vs. 157.8±24.8， P＜0.05） and invasion （84.4±15.1 vs. 135.6±16.7，P＜0.05） ability of A549 cell were also suppressed compared with control group after transfection. Down-regulation of miR-769-5p by transfected with miR-769-5p inhibitor could enhance the malignant phenotype of GLC-82 cells in vitro， including cell growth （P＜0.05）， colony formation （555.7±29.7 vs. 366.3±28.7，P＜0.05）， as well as cell migration （226.7±40.3 vs. 153.3±38.7，P＜0.05） and invasion （196.7±39.1 vs. 138.9±40.4，P＜0.05）. Conclusion The expression of miR-769-5p can inhibit the proliferation， migration and invasion of NSCLC cells.

Related Articles | Metrics

The effect of miR-21 on the stem cell characteristics of human tongue squamous cell carcinoma and cisplatin sensitivity

ZHANG Qijia，XU Hanfeng.

Chinese Clinical Oncology. 2017, 22 (9): 775.

Abstract ( 272 )

PDF（pc） (1167KB) ( 284 )

Save

Objective To investigate the effect of expression of miR-21 on the stem cell characteristics of human tongue squamous cell carcinoma and cisplatin sensitivity. Methods Human tongue squamous cell carcinoma SCC9 cells were cultured by adherent and suspension cultures to obtain SCC9a and SCC9f cells. The miR-21 mimics and miR-21 inhibitor were transfected to the SCC9f cells respectively. Stem cell related transcription factors （Oct3／4， Sox2， Nanog） and miR-21 expression was detected by quantitative real-time PCR（QPCR）. The proportion of ALDH positive cells was detected by ALDEFLOR kit. The cell proliferation was determined by MTT assay，and AnnexinV／PI method was used to measure cell apoptosis. Results The expression of Oct3／4， Sox2 and Nanog and the positive rate of ALDH in SCC9f cells was significantly higher than that of SCC9a cells. The inhibition rate and apoptosis ratio of SCC9f cells treated with cisplatin was lower than those of SCC9a cells. The expression of miR-21 in SCC9f was higher than that of SCC9a （P＜0.05）. The expression of miR-21 in SCC9m was higher than that of SCC9f （P＜0.05）， while that of SCC9i was lower than that of SCC9f （P＜0.05）. The expression of Oct3／4 in SCC9m cells was higher than that in SCC9f cells （P＜0.05）. The expression of Oct3／4， Sox2 and Nanog in SCC9i cells was significantly lower than that in SCC9f cells （P＜0.05）. The positive ratio of ALDH in SCC9a， SCC9m and SCC9i cells was significantly different from that in SCC9f cells （P＜0.05）. The apoptosis rate of SCC9f cells was lower than that of SCC9i cells，and higher than that of SCC9m cells （all P＜0.05）. Conclusion The SCC9f cultured by suspension culture method have stem cell characteristics， and more tolerable to cisplatin. Inhibition of miR-21 expression could enhance the sensitivity of SCC9 cells to cisplatin. It may be related to tumor stem cells which are regulated by the expression of miR-21.

Related Articles | Metrics

Expression and clinical significance of miRNA in malignant pleural effusion of lung adenocarcinoma

QIAN Qian， HAO Keke.

Chinese Clinical Oncology. 2017, 22 (9): 781.

Abstract ( 258 )

PDF（pc） (1904KB) ( 334 )

Save

Objective To investigate the expression of miRNA related to malignant pleural effusion in lung adenocarcinoma， and to investigate the relationship between the expression of miRNA and prognosis. Methods miRNA chip technique was used to screen the expression of malignant pleural effusion in 10 lung adenocarcinoma patients， and to analyze the possible correlation of miRNA with clinical prognosis. The expression of miRNA was detected by quantitative real-time PCR（QPCR）in 84 cases of malignant pleural effusion of lung adenocarcinoma， and the differential expression of miRNA was confirmed by clinical prognosis analysis. Results In 5 patients of progression free survival （PFS） more than 5 months and 5 patients of PFS less than 2 months， microarray screening revealed a total of 13 miRNAs expression changing ratio＞2 times. Expression of miR-146a， miR-16， miR-155， miR-484， miR-134， miR-141， miR-106b and miR-93 was detected in 84 patients with pleural effusion of different prognosis. It was revealed that the expression of miR-93 and miR-146a were different. Compared with patients with poor prognosis， the expression of miR-93 was increased by 2.41 times in patients with good prognosis； and the expression of miR-146a was decreased by 46％. Conclusion MiR-93 is highly expressed and miR-146a is lowly expressed in malignant pleural effusion of patients with better prognosis. They may be new molecular markers for the prognosis of patients with malignant pleural effusion.

Related Articles | Metrics

Expression of AKR1C3 and clinical significance in non-small cell lung cancer

CHEN Mi， JIA Lin， HAN Jianjun.

Chinese Clinical Oncology. 2017, 22 (9): 787.

Abstract ( 267 )

PDF（pc） (1108KB) ( 290 )

Save

Objective To investigate the expression of C3 subtype of aldosterone reductase family 1 （AKR1C3） in non-small cell lung cancer （NSCLC） and its clinical significance. Methods Eighty-eight cases of surgically resected NSCLC tissues and 83 cases of paraneoplastic normal tissues were collected from January 2013 to March 2016. The expression of AKR1C3 in the tissues were detected by real-time quantitative PCR （QPCR）， and the expression of AKR1C3 in NSCLC tissues and adjacent normal tissues were compared. The relationship between the expression of AKR1C3 in NSCLC tissue and the clinicopathological parameters of NSCLC （sex， age， TNM stage， tumor size， histological type， lymph node metastasis） was analyzed. Based on the follow-up data， the relationship between the AKR1C3 and the prognosis was analyzed. The receiver operating characteristic curve （ROC） was used to evaluate the effectiveness of AKR1C3 in the early diagnosis of NSCLC. Results The expression of AKR1C3 in the NSCLC group was （0.187±0.175）， lower than that in the adjacent normal tissues （1.079 ±0.384）， and the difference was statistically significant （P＜0.05）. The area under the NSCLC curve of tissue AKR1C3 was 0.982 （95％CI： 0.966-0.998）. The expression of AKR1C3 in NSCLC tissue were independent of sex， age， histological type and lymph node metastasis， but related with tumor size and TNM staging. The expression of AKR1C3 in tissue more than 3 cm was （0.095±0.055）， lower than （0.340±0.201） in tissue less than 3 cm （P＜0.05）. The expression of AKR1C3 in tissue of Ⅲ and Ⅳ was （0.094±0.058）， lower than （0.265±0.202） in tissue of Ⅰ and Ⅱ stage. The median OS of the whole group was 17.60 months. The median OS of the patients with AKR1C3 high level was 20.60 months， higher than that of the lower level 11.90 months， and the difference was statistically significant （P＜0.05）. Conclusion The expression of AKR1C3 in NSCLC tissue is decreased， and it is related to TNM stage， tumor size and prognosis. It may be related to the occurrence and development of NSCLC， and is valuable in NSCLC diagnosis and disease evaluation.

Related Articles | Metrics

Relationship between expression of serum thymidine kinase 1 and efficacy of pemetrexed regimen in advanced non-small cell lung cancer

HUANG Zhiyu， LI Jiancheng， ZHENG Buhong， QIAN Feiyu.

Chinese Clinical Oncology. 2017, 22 (9): 792.

Abstract ( 259 )

PDF（pc） (1082KB) ( 281 )

Save

Objective To investigate the relationship between expression of serum thymidine kinase 1 （TK1） and the efficacy of pemetrexed regimen in advanced non-small cell lung cancer （NSCLC）. Methods A total of 74 patients with advanced NSCLC diagnosed pathologically from January 2013 to January 2016 were enrolled in this study. All patients received pemetrexed monotherapy or platinum combination therapy. Peripheral blood samples from NSCLC patients were collected and serum levels of TK1 were detected by immunoblot enhanced chemiluminescence. The relationship between serum TK1 levels and clinical pathological parameters （sex， age， tumor size， differentiation， clinical stage， smoking history and lymph node metastasis） was analyzed. Meanwhile， peripheral blood samples from 88 healthy subjects were selected as controls. The RECIST1.1 version was used to evaluate the short-term effects of chemotherapy and the prognosis was followed up. The relationship between serum TK1 levels and prognosis was evaluated. Results TK1 level was （3.677±0.172） pmol／L （median： 3.665 pmol／L； four quantile： 2.618-4.423 pmol／L） in the NSCLC group， and （1.510± 0.072） pmol／L （median： 1.530 pmol／L； four quantile： 0.950-2.010 pmol／L）. The TK1 level was higher in NSCLC group than in control group and there was statistical significant differences （P＜0.05）. TK1 levels were not related to sex， age， smoking history and lymph node metastasis of NSCLC， but were related to tumor size， differentiation type and TNM stage. The serum level of TK1 was （4.362±0.210） pmol／L in tumor over 3 cm in size， higher than （2.914±0.217） pmol／L in tumor less than 3 cm in size （P＜0.05）. The serum TK1 level of the patients with low differentiation was （4.865±0.196） pmol／L， higher than （2.867±0.171） pmol／L of the high and middle differentiation （P＜0.05）. The serum TK1 level of TNM stage Ⅳ was （4.550±0.187） pmol／L， higher than （3.012±0.218） pmol／L of stage Ⅲ （P＜0.05）. The TK1 level of patients with chemotherapy sensitivity was （1.991±0.199） pmol／L （median： 2.360 pmol／L； four quantile： 1.360-2.560 pmol／L）， and of patients with chemotherapy resistance was （4.259±0.158） pmol／L （median： 4.250 pmol／L； four quantile： 3.570-4.870 pmol／L）. The sensitive TK1 level was higher in resistance group than in sensitive group （P＜0.05）. The progression-free survival of high-level TK1 （＞3.665 pmol／L） was 6.6 months， shorter than 8.5 months of low level of TK1 （P＜0.05）. Conclusion There was high expression of TK1 in serum of NSCLC patients， and tumor size， differentiation types and clinical stages were associated with higher TK1. The total effective rate is lower and shorter PFS in patients with higher level of TK1， suggesting a role in NSCLC development.

Related Articles | Metrics

Systematic review of efficacy and safety of elemene injection combined with conventional chemotherapy for malignant serous effusions

ZHANG Zhiyu， QIN Shukui.

Chinese Clinical Oncology. 2017, 22 (9): 797.

Abstract ( 189 )

PDF（pc） (2270KB) ( 309 )

Save

Objective To provide important reference for clinical rational drug use and scientific decision based on the systematic review of efficacy and safety of elemene injection combining with routine chemotherapy drugs in treating malignant serous effusions. Methods Papers and data of randomized controlled clinical trials （RCT） of elemene injection combining with routine chemotherapy drugs for malignant serous effusions published from Jan. 1996 to Feb. 2017 were retrieved by computer from the following databases： WanFang Data Knowledge Service Platform， China National Knowledge Infrastructure and Full-text database of Chinese Sci ＆ Tech Journals. The quality of materials was under assessment of Juni evaluation standards and Cochrane system evaluation method. Revman 5.0 software was used for Meta analysis and funnel analysis was used to evaluate publication bias. Results Seven hundred and thirty papers were searched preliminarily and 22 RCTs （1288 subjects） were bring to meta-analysis. In which overall response rate （RR=1.42，95％CI： 1.25-1.60；P＜0.01）and quality of life improvement rate（RR=2.08，95％CI： 1.76-2.47；P＜0.01） of combining group （elemene combining with chemotherapy） were significantly better than control group （only chemotherapy）. Compared with control group， the incidence of gastrointestinal reactions， myelosuppression and hepatic and renal impairment in combining group were obviously decreased， however， the incidence of fever reaction increased markedly. There was no significant difference of chest pain rate between the two groups （29.79％ vs. 22.27％） after intrapleural therapy （RR=1.37，95％CI： 0.96-1.96；P=0.08）.The Juni quality evaluation standard showed that the RCT quality evaluation was only in B and C and the GRADE system’s evidence quality was intermediate. Funnel analysis did not show any publication bias. Conclusion Elemene injection combining with chemotherapy drugs may have significant synergies effect. It is a good therapy choice for malignant serous effusions with the better safe as well as efficacy， improving the life quality and tolerability of the patients However， in view of the limitation of scientific research level at that time， the quality of original literatures included in this research are a little bit lower. Therefore the large-scale and high quality clinical researches including RCT or real world study （RWS） should be carried out to acquire further strong and more high evidence to support conclusion of this Meta analysis.

Related Articles | Metrics

Prognostic value of tumor deposit in gastric cancer patients

JIANG Huiqin， LI Qian， LI Wei， LI Hong， YU Yiyi， LIU Tianshu.

Chinese Clinical Oncology. 2017, 22 (9): 807.

Abstract ( 215 )

PDF（pc） (1262KB) ( 284 )

Save

Objective To examine the prognostic values of tumor deposits （TDs） in gastric cancer. Methods The patients underwent radical gastrectomy and histopathologically diagnosed as gastric cancer from April 2015 to January 2016 were involved. The relationship between the status of TDs and clinicopathological features of gastric cancer was analyzed. The 1-year disease-free survival (DFS) rate was calculated. Results The positive rate of TDs in 137 cases of gastric cancer was 24.8％. Univariate analysis showed that T／N stage and neural／vascular invasion were related to the positive expression of TDs. The 1-year DFS rates of the TD positive group and TD negative group were 59％ and 85％， respectively. In the Ⅰ／Ⅱ stage， the 1-year DFS rates of the TD positive group and TD negative group were 40％ and 91％， respectively. Conclusion The TD status was positively correlated with T／N stage and nerve／vascular invasion after radical gastrectomy. TD positive was a poor prognostic factor， indicatingearly relapse after radical gastrectomy. The prognostic value of TD was more significant in stage Ⅰ／Ⅱ gastric cancer patients.

Related Articles | Metrics

Analysis of prognostic and recurrence factors of pancreatic cancer received adjuvant chemotherapy

FANG Leping， XU Xiaoyan， JI Yu， HUANG Puwen.

Chinese Clinical Oncology. 2017, 22 (9): 812.

Abstract ( 222 )

PDF（pc） (949KB) ( 251 )

Save

Objective To investigate the prognostic and recurrence factors of pancreatic cancer patients treated with adjuvant chemotherapy， so as to improve the long-term survival of the patients with early detection of recurrence. Methods Seventy-seven pancreatic adenocarcinoma patients underwent resection with curative intent and received adjuvant chemotherapy from January 2008 to September 2015 were enrolled in this study. Results The median survival for all patients was 20.44 months. Univariate analysis identified differentiation，surgical margin status， tumor maximum diameter， intravascular cancer emboli， vascular invasion， lymph node metastasis， pre-operation CEA level， pre-operation neutrophil lymphocyte ratio （NLR） and postoperative chemotherapy were associated with prognosis. The multivariate analysis showed that lymph node metastasis， poorly differentiated， R1 resection and uncompleted adjuvant chemotherapy were negative prognosis factors. Univariate analysis of the maximum tumor size， T stage， vascular invasion and preoperative CEA levels was related to the recurrence of pancreatic cancer. Logistic regression analysis showed that invasion of blood vessels and elevated preoperative CEA levels were independent risk factors for recurrence of pancreatic cancer. Compared to patients without recurrence, patients with recurrence have shorter survival time. Conclusion Lymph node metastasis， low differentiation， R1 resection， and incomplete adjuvant chemotherapy are prognostic factors for pancreatic cancer patients receiving adjuvant chemotherapy. Pancreatic cancer patients with vascular invasion and preoperative CEA level were more likely to relapse， recurrence and survival time shorter， so these patients to early recurrence should pay attention to the assessment of the disease and the need for preoperative treatment.

Related Articles | Metrics

Efficacy and safety of stereotactic body radiotherapy in the management of oligometastatic tumor

LIU Jingli， QIU Yue， WANG Lian， XU Caiyun， QU Guangqiao， LI Xiangrong.

Chinese Clinical Oncology. 2017, 22 (9): 817.

Abstract ( 202 )

PDF（pc） (928KB) ( 327 )

Save

Objective To evaluate the efficacy and safety of stereotactic body radiotherapy for patients with oligometastatic tumor. Methods Eighty-five patients with 1-5 metastatic sites， life expectancy＞3 months， and also good performance status， which hospitalized from June 2011 to December 2016 were enrolled， SBRT therapy were performed for those patients， during this process， escalated doses of SBRT to all known metastatic sites. The primary end points were local control rate and toxicity. Secondary end points were overall survival（OS） and progression-free survival（PFS）. Tumor response and Local control were defined using EORTC-RECIST Criteria v. 1.1. Acute and late toxicity were scored by the RTOG evaluation criterion. The survial rates were calculated by Kaplan-Meier analysis. The differences among the modalities were evaluated using the Log-rank test. Results A total of 85 patients， 187 metastastic sites complete the treatment，the median follow-up of 25 months， local control rate of the whole team was 66.8％， local control rate of the three treatment modalities 24， 30， 36Gy were 39.0％， 79.0％， 84％， respetively， showing a significant difference between the groups（P＜0.05）.The medium time of PFS was 7.8 months. The 1-， 2-， 3-year progression-free survival rate was 33.3％, 25.0％, 23.0％. The medium overall survival time was 25 months. The 1-， 2-， 3-year survival rate was 80.5％，75.6％，70.6％. Four patients had acute toxic reactions over grade 3, including 2 patients with pulmonary metastasis proved to be radioactive pneumonia 2 months later, and one patient with liver metastases occurred severe vomiting and elevated transaminase, and one patient with liver, lung and bone metastasis occurred grade 4 bone marrow suppression.Conclusion Patients with oligometastatic disease can be identified， in a safe treatment scope， SBRT can achieve good local control rate， with tolerable adverse effects.

Related Articles | Metrics

Value analysis of contrast-enhanced ultrasound combined with elastography in the diagnosis of thyroid carcinoma

HUANG Shengxi， JIN Weikui， SI Qin.

Chinese Clinical Oncology. 2017, 22 (9): 823.

Abstract ( 195 )

PDF（pc） (1135KB) ( 422 )

Save

Objective To explore the clinical value of contract enhanced ultrasound （CEUS） and elastography in the diagnosis of thyroid carcinoma. Methods From March 2014 to December 2015， 168 lesions of 139 patients with thyroid nodes were enrolled and divided into three groups according to the testing means. There were CEUS group of 52 patients with 66 thyroid nodes， elastography group of 56 patients with 68 thyroid nodes and CEUS combine with elastography group of 31 patients with 34 thyroid nodes. All thyroid node lesions were confirmed via needle aspiration biopsy. The pathology， routine color Doppler ultrasound findings and imaging findings of each group were analyzed， and the efficacy of each group in the diagnosis of thyroid cancer was analyzed by receiver operating characteristic curve （ROC）. Results One hundred and sixty-eight thyroid nodes （including 109 benign and 59 malignant lesions） of 139 patients were confirmed by pathology. In CEUS group， 41 benign and 25 malignant thyroid nodes were diagnosed. In elastography group， 47 benign and 21 malignant thyroid nodes were diagnosed. In CEUS combine with elastography group， 24 benign and 10 malignant thyroid nodes were diagnosed. The ROC curve area of benign and malignant thyroid nodes by the CEUS combine with elastography groups， elastography， CEUS diagnosed were 0.924， 0.883， 0.847 respectively. The sensitivity， specificity and accuracy by the CEUS combine with elastography groups， elastography， CEUS diagnosed were 70.0％， 75.0％， 73.0％； 96.8％， 94.4％， 94.6％ and 90.0％， 77.7％， 80.0％. The diagnostic efficacy of CEUS combined with elastography is superior to that of elastography and CEUS alone. Conclusion CEUS combine with elastography can obviously improve the diagnosis accuracy of thyroid carcinoma. It has good clinical value in clinic.

Related Articles | Metrics

Clinical investigation of fractional exhaled nitric oxide in predicting radiation pneumonia

TAO Hua，GUO Yesong，ZHU Huanfeng，QIAN Pudong.

Chinese Clinical Oncology. 2017, 22 (9): 827.

Abstract ( 218 )

PDF（pc） (895KB) ( 271 )

Save

Objective To investigate the value of fractional exhaled nitric oxide （FeNO） in predicting radiation pneumonia. Methods One hundred and thirty-one thoracic tumor patients from Aug 2016 to Feb 2017 were received FeNO test before and after radiotherapy， and the relationship between FeNO of large airway （50 ml／s）， small airway （200 ml／s）， pulmonary alveolus and radiation pneumonia were analyzed. Results Of the 131 patients， the average FeNOs of large airway， small airway and pulmonary alveolus were 19.86 ppb， 9.49 ppb and 2.84 ppb before radiation. FeNO level of pulmonary alveolus increased significantly after radiotherapy（P=0.015）. After radiotherapy， grade 1， 2 and 3 radiation pneumonia were found in 43 patients， 70 patients and 18 patients. The FeNO level of large airway， small airway and pulmonary alveolus and had no relation with classification of radiation pneumonia. Conclusion FeNO of pulmonary alveolus rose significantly after radiotherapy. However， the FeNO level before and after radiotherapy cannot predict radiation pneumonia.

Related Articles | Metrics

Clinical observation of BR-TRG-I type body cavity hyperthermic perfusion instrument on hyperthermic intravesical chemotherapy

WANG Yu， LI Yugang， HONG Jian， WANG Yuandong， LI Weiming， LUO Xiaojun， ZHOU Yuchen.

Chinese Clinical Oncology. 2017, 22 (9): 831.

Abstract ( 256 )

PDF（pc） (1335KB) ( 243 )

Save

Objective To explore the feasibility and clinical effect of BR-TRG-I type body cavity hyperthermic perfusion instrument for bladder perfusion chemotherapy in patients with non-muscular invasive bladder cancer. Methods From June 2014 to January 2015， a total of 8 non-muscle-invasive bladder cancer patients were treated with hyperthermic intravesical chemotherapy by BR-TRG-I type body cavity hyperthermic perfusion instrument in our hospital. The perfusion rate of solution was set as 200 ml／min， with the temperature of 43 ℃ for 1 hour， 1 time per week for 8 weeks， then changed to 1 time monthly. Chemotherapy drugs were selected with pirarubicin hydrochloride （THP）， 30 mg THP was dissolved in 1500 ml perfusate. Vital signs of the patients was monitored for real time during the process. Cystoscopy was performed every 3 months after TUR-BT， and the recurrence rate was observed for 2 years. Results In the process of perfusion， the BR-TRG-I type hyper thermic body cavity perfusion treatment system could achieve the continuous circulation of thermostatic perfusion， and the vital signs of the patients could keep stable. After 2 years of follow-up， all patients had no recurrence， including 2 cases of patients with voiding needling sensation， after the patients drank water， the symptoms could alleviate. Conclusion The method of bladder hyperthermic perfusion chemotherapy on non-muscle-invasive bladder cancer patients who have undergone TUR-BT proved to be an useful and effective method in prevention of non-muscle-invasive bladder cancer recurrence. The technology and methods is safe and feasible， which can achieve the continuous circulation of thermostatic perfusion， and has very bright clinical application prospect.

Related Articles | Metrics

Clinical control trial of different hormone for intracranial tumor edema after subtotal resection of gliomas

ZHAO Ying， WANG Shoujie， ZHAO Haikang.

Chinese Clinical Oncology. 2017, 22 (9): 835.

Abstract ( 245 )

PDF（pc） (1277KB) ( 316 )

Save

Objective To evaluate the clinical efficacy and safety of methylprednisolone for the treatment of peritumoral edema after glioma subtotal resection. Methods From Jun 2015 to Jan 2016， a total of 95 cases of glioma which underwent subtotal resection were selected and randomly divided into methylprednisolone group（n=32）， dexamethasone group（n=33） and control group（n=30）. After operation， methylprednisolone and dexamethasone groups were treated with equivalent dose of methylprodnisolone 40 mg and dexamethasone 10 mg and twice a day at 8：00 and 16：00. The control group was only applied with dehydration treatment. Based on consensus on the drug treatment of peritumoral brain edema （1st edition）， the edema index （EI） values of each group were respectively tested by MRI at the different time points including 72 hours， 5 days， 14 days and 28 days after subtotal resection. The adverse reactions of these 3 groups were monitored during the treatment. Results During the peak period of edema which appeared from the 3rd to 7th days， although methylprednisolone was more effective to control the peritumoral edema comparing with dexamethasone， there was no obvious statistical difference （P＞0.05）. After 14 days， the EI values of methylprednisolone group and dexamethasone group were 2.58±1.02 and 3.67±1.71 respectively， and the difference was statistically significant （P=0.023）. On the 28th day， the EI values were 1.76±0.72 and 2.14±1.13 respectively， and difference was statistically significant （P=0.01）. Both of these two groups had their own defect due to the adverse drugs reactions， dexamethasone could influence the internal environment and the methylprednisolone would cause gastrointestinal stress response. Conclusion With equivalent dose， methylprednisonone is more efficient to control peritumoral edema after subtotal resection of gliomas than dexamethasone. Furthermore， adverse reactions during the treatment should be actively prevented.

Related Articles | Metrics

Progression in anti-angiogenesis agents for soft tissue sarcoma

YIN Qiliang，WU Di，YU Yingying，LAN Shijie.

Chinese Clinical Oncology. 2017, 22 (9): 839.

Abstract ( 196 )

PDF（pc） (948KB) ( 282 )

Save

Soft tissue sarcoma （STS）constitutes a heterogeneous group of rare solid tumors of mesenchymal cell origin with different clinicopathological features. The outcome of patients with advanced STS and the efficacy of chemotherapy are poor. Therefore， new therapeutic strategies are desperately needed to improve treatment efficacy. With deeper understanding of the biological behavior of STS， several emerging anti-angiogenesis agents are used in clinic and have achieved good efficacy， which may bring breakthrough to the treatment of STS and improve the prognosis. In this review， we will discuss the current advances in anti-angiogenesis agents for STS.

Related Articles | Metrics

Progression of VEGFR-TKI in advanced non-small cell lung cancer

JIANG Kan，HUANG Cheng.

Chinese Clinical Oncology. 2017, 22 (9): 845.

Abstract ( 249 )

PDF（pc） (940KB) ( 386 )

Save

Angiogenesis plays an important role in tumor genesis and development. Therefore， anti-angiogenic therapy has become an important part in cancer therapy and throughout the entire therapy process. Vascular endothelial growth factor receptor tyrosine kinase inhibitor （VEGFR-TKI） is small molecular anti-angiogenic drug. This article introduces the domestic and international listed and researching VEGFR-TKIs. The models of single-agent／combined with chemotherapy drugs／combined with targeted drugs can improve the objective response rates（ORR）of advanced non-small cell lung cancer （NSCLC）， lengthen progression-free survival（PFS）. But it was failed to lengthen overall survival（OS）. And the adverse effects of VEGFR-TKIs were greater. How to improve the efficacy and reduce adverse effects will be the direction of future research.

Related Articles | Metrics

Progression of optimizing strategy of neoadjuvant therapy for borderline resectable pancreatic cancer

ZHANG Yu， YAO Lin， LIU Xiufeng.

Chinese Clinical Oncology. 2017, 22 (9): 851.

Abstract ( 170 )

PDF（pc） (881KB) ( 288 )

Save

Pancreatic cancer is considered as one of the most aggressive malignancies with poor prognosis. Only a few newly diagnosed patients are possible candidates for curative resection. With the development of medical technology， there is a new subtype of pancreatic cancer called borderline resectable pancreatic cancer （BRPC） that has been distinguished from resectable and unresectable cases. BRPC has low R0 resection rate and high risk of recurrence. Neoadjuvant therapy is playing an important role in BRPC aiming to improve the R0 resection rate and prolong survival. How to optimize neoadjuvant therapy strategy and improve prognosis of BRPC is worth of attention.

Related Articles | Metrics

Progression of clinical utility of circulating cell-free DNA in colorectal cancer

ZHU Yiwen， LI Qi.

Chinese Clinical Oncology. 2017, 22 (9): 855.

Abstract ( 202 )

PDF（pc） (914KB) ( 417 )

Save

Colorectal cancer is one of most common malignant tumor of the gastrointestinal tract and it is difficult to early diagnosis. Rencently， with the development of screening for high-risk individuals and improvement of endoscopy， the early diagnosis of colorectal cancer has improved largely. However， those with obvious symptoms have developed into advanced stage and their prognosis was poor. Circulating cell-free DNA （cfDNA） as a new type of tumor biomarkers has been widely concerned recently. It has great potential for choosing chemotherapy regiems， evaluating therapeutic effect and predicting prognosis. In this paper， clinical utility of circulating cell-free DNA in colorectal cancer will be reviewed.

Related Articles | Metrics

标准刊号：	ISSN 1009-0460
	CN 32-1577/R